Maternal Serum Screening: Results Disclosure, Anxiety, and Risk Perception

ABSTRACT

Although increased maternal anxiety following the disclosure of positive second-trimester maternal serum screen (MSS) results has been well documented, how this anxiety correlates with the method of results disclosure has not been well defined. This pilot study aimed to determine how abnormal second-trimester MSS results are disclosed, the level of anxiety experienced by women as a result of this disclosure, and the accuracy of their risk perception. Women referred for prenatal genetic counseling were asked to complete a questionnaire including demographics, standardized Spielberger State-Trait Anxiety Inventory, results disclosure information, and perceived risk. Of the 561 questionnaires distributed, 388 (69.2%) women chose to participate. Of the 136 participants referred for an abnormal MSS, 125 (91.9%) were aware of this indication and elected to complete the results disclosure portion of the questionnaire. The average anxiety level was not significantly different based on the method of results disclosure or who reported the results. We did not identify a definite cause for the anxiety experienced by women receiving abnormal MSS results; however, this study illustrates the need for further research to identify factors that contribute to the elevated anxiety experienced by these women.

KEYWORDS

Anxiety - serum screen - results disclosure

REFERENCES

• 1 Hertling-Schaal E, Perrotin F, de Poncheville L, Lansac J, Body G. [Maternal anxiety induced by prenatal diagnostic techniques: detection and management].  Gynecol Obstet Fertil. 2001;  29 440-446
• 2 Gekas J, Gondry J, Mazur S, Cesbron P, Thepot F. Informed consent to serum screening for Down syndrome: are women given adequate information?.  Prenat Diagn. 1999;  19 1-7
• 3 Goel V, Glazier R, Summers A, Holzapfel S. Psychological outcomes following maternal serum screening: a cohort study.  CMAJ. 1998;  159 651-656
• 4 Green J M. Serum screening for Down's syndrome: experiences of obstetricians in England and Wales.  BMJ. 1994;  309 769-772
• 5 Marteau T M, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI).  Br J Clin Psychol. 1992;  31(Pt 3) 301-306
• 6 Milunsky A. Genetic Disorders and The Fetus: Diagnosis, Prevention and Treatment. 4th ed. Boston; The Johns Hopkins University Press 1998
• 7 Nussbaum R L, McInnes R R, Willard H F. Thompson and Thompson Genetics in Medicine 6th ed. W.B. Saunders Co. 2001: 359-374
• 8 Kuller J A, Laifer S A. Contemporary approaches to prenatal diagnosis.  Am Fam Physician. 1995;  52 2277-2283 2285-2286
• 9 Rausch D N, Lambert-Messerlian G M, Canick J A, Delzell J E. Participation in maternal serum screening for Down syndrome, neural tube defects, and trisomy 18 following screen-positive results in a previous pregnancy.  West J Med. 2000;  173 180-183
• 10 Hoskovec J, Mastrobattista J M, Johnston D, Kerrigan A, Robbins-Furman P, Wicklund C A. Anxiety and prenatal testing: do women with soft ultrasound findings have increased anxiety compared to women with other indications for testing?.  Prenat Diagn. 2008;  28 135-140
• 11 Robertson E, Grace S, Wallington T, Stewart D E. Antenatal risk factors for postpartum depression: a synthesis of recent literature.  Gen Hosp Psychiatry. 2004;  26 289-295
• 12 Schneider K M, Strecker M N, Promecene P A, Monga M. Racial bias in patient selection of an obstetrician.  South Med J. 2005;  98 409-410
• 13 Abuelo D N, Hopmann M R, Barsel-Bowers G, Goldstein A. Anxiety in women with low maternal serum alpha-fetoprotein screening results.  Prenat Diagn. 1991;  11 381-385